Mississippi Sends ‘Right to Try’ Cannabis Bill to Governor — And the Framing Matters

Mississippi’s Cannabis Inquirer’s legislative tracker has passed the Right to Try Medical Cannabis Act and sent it to the governor’s desk. If signed, the law would take effect July 1, 2026, giving physicians broader discretion to recommend medical cannabis to qualifying patients — a meaningful expansion of the state’s existing medical program.

On the surface, this is a standard medical cannabis expansion. But the way Mississippi got here is worth understanding.

“Right to try” is a political frame that has proven effective at crossing ideological lines in conservative states. The language borrows from the established right-to-try movement — federal and state laws passed in the 2010s allowing terminally ill patients access to experimental treatments — and maps it onto cannabis. It shifts the question from “do we trust marijuana?” to “should government stand between a patient and their doctor?” In a state that has consistently resisted cannabis liberalization through traditional channels, that reframing is the difference between a dead bill and one headed to the governor.

The practical effect of the bill is also real. Physicians in Mississippi’s existing medical program have operated under narrow qualifying condition lists and restricted recommendation latitude. The new law broadens that discretion — in line with the clinical reality that many conditions don’t fit neatly into a statutory list.

The second-order implication extends beyond Mississippi. “Right to try” cannabis legislation has been explored in several Southern and Plains states as a mechanism to expand access without the political liability of a “legalization” vote. If Mississippi’s bill is signed and implemented without significant controversy, it provides a replicable template. Georgia, where SB 220 is also advancing, is watching. So are advocates in Alabama and Tennessee’s crackdown on hemp-derived products.

The caveat: gubernatorial signatures in these states are not guaranteed, and implementation quality matters as much as the law itself. Mississippi’s existing medical program has faced operator shortages and patient access issues since launch. Whether expanded physician discretion translates into broader real-world access depends on whether there are enough licensed dispensaries and products to meet demand.

That piece remains unsolved. The bill addresses the prescription side of the equation. The supply side is a separate problem.

Ethan Vale covers federal cannabis policy, DEA regulation, and congressional action for CannabisInquirer.com.